Related Topics News -

     
 Detail   |   Print    Next page > 
     
《業績》荃信生物中期扭虧賺2.03億元人民幣
2026-08-20T  
荃信生物QX027N獲慢性阻塞性肺疾病及慢性鼻竇炎伴鼻息肉適應症臨床試驗默示許可
2026-08-03T  
荃信生物合作夥伴同步進行2.78億美元私募融資 擬於納斯達克資本市場上市
2026-07-30T  
《業績》荃信生物全年純利3.14億人民幣 虧轉盈
2026-03-29T  
荃信生物魯塞奇塔單抗注射液上市申請獲受理
2026-03-09T  
荃信生物共計回購248.78萬股 涉資5,075萬
2026-02-06T  
荃信生物QX030N/CLD-423完成I期臨床試驗首批受試者給藥
2026-01-14T  
荃信生物共計回購157.58萬股 總額3,116萬元
2026-01-07T  
荃信生物(02509.HK)授出QX027N商業化權利 可獲高達7億美元付款
2025-12-22T  
荃信生物收到Caldera里程碑付款500萬美元
2025-12-09T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.